Galunisertib, an ALK5 inhibitor, showed promising results in in vitro and in vivo cancer studies [250,251], passed the preclinical investigation [252], and has already been enrolled in several clinical studies for cancer management [253,254,255,256,257,258,259,260]. The gene discussed is TGFBR1; the disease is cancer.